Guidant COO Neels’ adieu
This article was originally published in The Gray Sheet
Executive Summary
Guido Neels retires Nov. 30, following former CEO Ron Dollens, who left the company Nov. 15 after agreeing to a new merger deal with Johnson & Johnson. Neels will serve as a special advisor to Chairman and CEO James Cornelius through the end of the year, according to a Nov. 30 Securities & Exchange Commission filing. He will also represent the firm's interests to AdvaMed. Before becoming COO in May 2004, Neels served as a group chairman...
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.